Nascent Biotech NBIO · USD

Its shares trade under the ticker NBIO. It has been listed since 6 June 2012. In the fiscal year to 31 March 2022, it reported revenue of $1.0m and a net loss of $470,390. At that date it held total assets of $105,414 and shareholders' equity of −$671,476.

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The company owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The firm is exploring Pritumumab in its use against viruses. The firm is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Sean CarrickPresident, Secretary, Director, since 2014$252,000
• Mr. Lowell HoldenChief Financial Officer, Chief Accounting Officer, Director$180,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.